Trial Profile
A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Corticosteroid; Cyclophosphamide; Diphenhydramine; Doxorubicin; Filgrastim; Methylprednisolone; Paracetamol; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms GATHER
- Sponsors Genentech
- 03 May 2019 Results of exposure-response analysis using data from six clinical trials in patients with CD20+ B-cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN, and GAUSS) published in the British Journal of Clinical Pharmacology
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.